View Older Stories View More Recent Stories
-
CIGNA (CI) PT Raised to $338 at TD Cowen; 'Two Key Overhangs Removed'
-
Cigna Corp. (CI) Tops Q4 EPS by 20c, Beats on Revenue; Offers FY26 Guidance
-
Cigna Settles FTC Insulin Case, Commits To Overhauling Drug Pricing - Reuters
-
Top Blue Chip Stocks for Growth and Value According to WarrenAI
-
Cigna Corp. (CI) call put ratio 3.2 calls to 1 put
-
BofA: 'Cigna (CI) is our top MCO pick'
-
Cigna Corp. (CI) call put ratio 1 call to 4.3 puts
-
Hunterbrook Research accuses Big Three health insurers of using shell companies
-
Cigna Corp. (CI) And Others Watch Amid Circulating Online Research Report
-
BofA unveils its top 10 U.S. ideas for Q1 2026
-
BofA: 'our Top 10 Ideas include nine Buys and one Underperform across nine industries'
-
UnitedHealth, Humana, Cigna fall after Trump comments on insurance pricing
-
Trump: Insurance Companies Need to Get Their Prices Down
-
TD Cowen Reiterates Buy Rating on CIGNA (CI)
-
CIGNA (CI) Recovery Highly Likely in 2027 - Cantor Fitzgerald
-
TD Cowen: 'Our Best Idea for 2026 is CIGNA (CI)'
-
BofA Adjusts US 1 List
-
CIGNA (CI) PT Lowered to $294 at Bernstein SocGen Group
-
CIGNA (CI) PT Lowered to $333 at TD Cowen
-
Cigna CEO David Cordani acquires 4,134 shares at $241.88
-
CIGNA (CI) PT Lowered to $350 at Raymond James
-
CIGNA (CI) PT Lowered to $310 at Jefferies
-
Cigna Corp. (CI) Tops Q3 EPS by 19c, Beats on Revenue; Offers FY25 EPS Guidance
-
Cigna Corp. (CI) call put ratio 1.8 calls to 1 put into quarter results
-
Evernorth launches rebate-free pharmacy benefit model to cut drug costs
-
Cigna Corp. (CI) to end drug rebates in many private health plans in 2027
-
Cigna Corp. (CI) Declares $1.51 Quarterly Dividend; 2% Yield
-
CIGNA (CI) PT Lowered to $325 at Wolfe Research
-
Trump: Working On Lowering Cost Of Health Insurance
-
UBS Reiterates Buy Rating on CIGNA (CI)
-
Cantor Fitzgerald Reiterates Overweight Rating on UnitedHealth Group (UNH)
-
Cantor Fitzgerald Reiterates Overweight Rating on Tenet Healthcare (THC)
-
Cantor Fitzgerald Reiterates Overweight Rating on Elevance (ELV)
-
Cantor Fitzgerald Reiterates Overweight Rating on CIGNA (CI)
-
Bernstein Weighs In on CIGNA (CI) Stock Following Shields Investment
-
Cigna Corp. (CI) files mixed shelf
-
Evernorth invests $3.5 billion in specialty pharmacy firm Shields
-
Cantor Fitzgerald Reiterates Overweight Rating on CIGNA (CI)
-
Gilead stock falls after CVS holds off adding HIV prevention shot to plans
-
CIGNA (CI) PT Lowered to $350 at Guggenheim
-
Cantor Fitzgerald Reiterates Overweight Rating on CIGNA (CI)
-
Cigna Corp. (CI) Tops Q2 EPS by 4c, Beats on Revenue; Offers FY25 EPS Guidance
-
Cigna Corp. (CI) 30-day option implied volatility flat
-
Humana (HUM) Healthcare stocks on watch after Centene withdraws guidance
-
RBC Capital Reiterates Outperform Rating on CIGNA (CI)
-
Health Insurers To Promise Changes To Preapproval Process - WSJ
-
CIGNA (CI) seen as a great stock for volatile times - Oppenheimer
-
Medicare Pharmacy Benefit Manager Limits Stripped From Tax Bill - Bloomberg
-
Cigna Healthcare (CI) Unveils Industry-Leading AI-Powered Digital Tools for a Simple and Reliable Customer Experience
-
Cigna Corp. (CI) Announces Appointment of Michael J. Hennigan to Board of Directors
